JP2012514597A5 - - Google Patents

Download PDF

Info

Publication number
JP2012514597A5
JP2012514597A5 JP2011544414A JP2011544414A JP2012514597A5 JP 2012514597 A5 JP2012514597 A5 JP 2012514597A5 JP 2011544414 A JP2011544414 A JP 2011544414A JP 2011544414 A JP2011544414 A JP 2011544414A JP 2012514597 A5 JP2012514597 A5 JP 2012514597A5
Authority
JP
Japan
Prior art keywords
lcpufa
acid
administered
therapeutic agent
fatty acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011544414A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012514597A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/006749 external-priority patent/WO2010077358A1/en
Publication of JP2012514597A publication Critical patent/JP2012514597A/ja
Publication of JP2012514597A5 publication Critical patent/JP2012514597A5/ja
Pending legal-status Critical Current

Links

JP2011544414A 2009-01-02 2009-12-30 内因性プラスマローゲン量を増加させる方法 Pending JP2012514597A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20417009P 2009-01-02 2009-01-02
US61/204,170 2009-01-02
PCT/US2009/006749 WO2010077358A1 (en) 2009-01-02 2009-12-30 Methods for increasing endogenous plasmalogen levels

Publications (2)

Publication Number Publication Date
JP2012514597A JP2012514597A (ja) 2012-06-28
JP2012514597A5 true JP2012514597A5 (enExample) 2014-07-24

Family

ID=42310073

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011544414A Pending JP2012514597A (ja) 2009-01-02 2009-12-30 内因性プラスマローゲン量を増加させる方法

Country Status (10)

Country Link
US (1) US20110275600A1 (enExample)
EP (1) EP2373161A4 (enExample)
JP (1) JP2012514597A (enExample)
CN (1) CN102271502A (enExample)
AU (1) AU2009333809A1 (enExample)
CA (1) CA2747582A1 (enExample)
MX (1) MX2011007188A (enExample)
RU (1) RU2011132386A (enExample)
WO (1) WO2010077358A1 (enExample)
ZA (1) ZA201105665B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2403491A2 (en) * 2009-03-04 2012-01-11 Nestec S.A. Alkylglycerols and alkoxyglycerols for increasing endogenous plasmalogen levels in mammals
CN103314291B (zh) * 2010-12-28 2016-05-11 藤野脑研究株式会社 通过血液样品判定痴呆症用的检验方法
JP5934483B2 (ja) * 2011-09-05 2016-06-15 学校法人帝京大学 リン脂質結合型dha増加剤
JP5997887B2 (ja) * 2011-09-05 2016-09-28 学校法人帝京大学 経口投与剤
JP7704407B2 (ja) * 2021-08-04 2025-07-08 株式会社 レオロジー機能食品研究所 がん治療用組成物
JP2023108631A (ja) * 2022-01-26 2023-08-07 大道 藤本 ドッグフード

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050027004A1 (en) * 1993-06-09 2005-02-03 Martek Biosciences Corporation Methods of treating senile dementia and Alzheimer's diseases using docosahexaenoic acid and arachidonic acid compositions
US20070004670A1 (en) * 1998-07-31 2007-01-04 Richard Wurtman Compositions containing citicoline, and methods of use thereof
US8052992B2 (en) * 2003-10-22 2011-11-08 Enzymotec Ltd. Glycerophospholipids containing omega-3 and omega-6 fatty acids and their use in the treatment and improvement of cognitive functions
US20080033027A1 (en) * 2005-03-21 2008-02-07 Vicus Therapeutics Spe 1, Llc Drug combination pharmaceutical compositions and methods for using them
US20080044487A1 (en) * 2006-05-05 2008-02-21 Natural Asa Anti-inflammatory properties of marine lipid compositions
EP2145181B1 (en) * 2007-04-13 2012-12-26 Phenomenome Discoveries Inc. Methods for the diagnosis and risk assessment of plasmalogen deficiency mediated diseases of aging

Similar Documents

Publication Publication Date Title
JP2012514597A5 (enExample)
Jiang et al. Omega-3 polyunsaturated fatty acid biomarkers and risk of type 2 diabetes, cardiovascular disease, cancer, and mortality
JP2017526623A5 (enExample)
Donadio et al. The role of fish oil/omega-3 fatty acids in the treatment of IgA nephropathy
NZ599067A (en) Fatty acid niacin conjugates and their uses
RU2019110681A (ru) Фармацевтическая композиция
JP2007504225A5 (enExample)
JP2012502090A5 (enExample)
JP2008519796A5 (enExample)
UA89207C2 (ru) Применение длинноцепочечных полиненасыщенных жирных кислот для получения жидкой питательной смеси для кормления детей
CA2275060A1 (en) Novel triglyceride and composition comprising the same
RU2007137986A (ru) Композиции и применение моно- и полиеновых кислот для разжижения флюидов, желированных вязкоупругими пав
BRPI0418921A (pt) uso de ácidos graxos poliinsaturados, composição nutricional, e, uso de uma composição
WO2008103753A3 (en) Oxylipins from long chain polyunsaturated fatty acids and methods of making and using the same
JP2011501661A5 (enExample)
JP2014111643A5 (enExample)
RU2014102958A (ru) Сложные эфиры для лечения офтальмологических воспалительных заболеваний
JP2021137035A5 (ja) 高度不飽和脂肪酸のトリグリセリドを含む組成物
JP2012509292A5 (enExample)
JP2016501248A5 (enExample)
Ahmmed et al. Fish roe phospholipids and health: Composition, extraction, storage and brain health application
JP2017516811A5 (enExample)
EP2373161A1 (en) Methods for increasing endogenous plasmalogen levels
JP2012513380A5 (enExample)
Roy et al. Long chain polyunsaturated fatty acid (LC-PUFA) composition of fish sperm: nexus of dietary, evolutionary, and biomechanical drivers